MAPKAP1

Across TCGA pan-cancer cohorts, MAPKAP1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAPKAP1 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MAPKAP1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAPKAP1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where MAPKAP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.563	0.825	.011	16	view →
LSCC	DFS	Quartile	All	0.698	0.931	.008	11	view →
LUAD	DFS	Tertile	III,IV	0.790	0.496	.037	4	view →
GBM	DFS	Median	All	0.411	0.221	.029	3	view →
PDAC	OS	Median	III,IV	0.877	0.610	.021	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAPKAP1–HNSC (DFS)

Open the HNSC breakdown →